drugset / Trial / NCT01412736
A Phase IIa Study of KHK4563
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a double-blind, placebo-controlled dose-ranging study of KHK4563 to evaluate the effect of multiple-dose subcutaneous administration of KHK4563 on the annual asthma exacerbation rate in adult subjects with uncontrolled, suspected eosinophilic asthma.
Timeline
- Start
- 2011-08
- Primary completion
- 2013-07
- Completion
- 2013-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KHK4563 | Unknown | 2 mg | Subcutaneous |
| Subject | KHK4563 | Unknown | 20 mg | Subcutaneous |
| Subject | KHK4563 | Unknown | 100 mg | Subcutaneous |